
Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/020001		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR §1.98(b))		Serial No.		09/486,086		
		Applicant		Haruhiko Yokoi et al.		
		Filing Date		February 18, 2000		
		Group		IDS Filed July 13, 2000		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
L.C.	5,362,623	November 8, 1994	Vogelstein et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
L.C.	Cho et al., "Crystal structure of a p53 tumor suppressor - DNA complex: understanding tumorigenic mutations," <i>Science</i> 265:346-355 (1994).					
	Kilby et al., "Site-specific recombinases: tools for genome engineering," <i>Trends Genet.</i> 9(12):413-421 (1993).					
	McLure and Lee, "How p53 binds DNA as a tetramer," <i>The EMBO Journal</i> 17(12):3342-3350 (1998).					
	Shujunsha Co., Ltd., "p53-molecular mechanisms of tumor-suppression and clinical applications," Translations of relevant sections extracted from the review, Saibo-Kougaku Supplement, <i>BioReview Series</i> p. 42 and 48 (1998).					
↓	Zambetti et al., "Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element," <i>Genes & Development</i> 6:1143-1152 (1992).					
EXAMINER				DATE CONSIDERED 9/18/02		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						